Roche axes two pipeline COVID drugs as pandemic hits Q1 pharma salesRoche has axed two mid-stage COVID drugs from its development pipeline, according to a first quarter results statement Share XRoche axes two pipeline COVID drugs as pandemic hits Q1 pharma saleshttps://pharmaphorum.com/news/roche-axes-two-pipeline-covid-drugs-as-pandemic-hits-pharma-sales/
NICE says yes to Novartis’ multiple sclerosis therapy KesimptaNovartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just Share XNICE says yes to Novartis’ multiple sclerosis therapy Kesimptahttps://pharmaphorum.com/news/nice-says-yes-to-novartis-multiple-sclerosis-therapy-kesimpta/
Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says RocheRoche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal Share XEvrysdi has ‘real world impact’ on lives of babies with severe SMA, says Rochehttps://pharmaphorum.com/news/evrysdi-has-real-world-impact-on-lives-of-babies-with-severe-sma-says-roche/
Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialAntios has raised $96 million in Series B financing to support the ongoing phase 2 development of its Share XRace for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialhttps://pharmaphorum.com/news/race-for-hepatitis-b-drug-intensifies-as-antios-raises-96m-for-phase-2-trial/
TG Therapeutics completes FDA filing for Roche challenger in CLLTG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab Share XTG Therapeutics completes FDA filing for Roche challenger in CLLhttps://pharmaphorum.com/news/tg-therapeutics-completes-fda-filing-for-roche-challenger-in-cll/
Roche stops dosing in trial of Huntington’s disease hopeful tominersenRoche has stopped dosing in a phase 3 trial of tominersen, a potential Huntington’s disease (HD) drug developed Share XRoche stops dosing in trial of Huntington’s disease hopeful tominersenhttps://pharmaphorum.com/news/roche-stops-dosing-in-huntingtons-disease-trial/
Roche launches test to monitor emerging coronavirus variantsRoche has launched a new test that will help monitor emerging variants of the SARS-CoV-2 coronavirus. In a Share XRoche launches test to monitor emerging coronavirus variantshttps://pharmaphorum.com/news/roche-launches-test-to-monitor-emerging-coronavirus-variants/
Roche expands COVID testing portfolio with $1.8bn GenMark dealRoche has said it will pay $1.8 billion for molecular testing company GenMark, boosting the Swiss company’s diagnostic Share XRoche expands COVID testing portfolio with $1.8bn GenMark dealhttps://pharmaphorum.com/news/roche-expands-covid-testing-portfolio-with-1-8bn-genmark-deal/
Roche’s Tecentriq loses bladder cancer use as FDA crackdown continuesRoche’s Tecentriq is the latest medicine to fall foul of a crackdown by the FDA on drugs that Share XRoche’s Tecentriq loses bladder cancer use as FDA crackdown continueshttps://pharmaphorum.com/news/roches-tecentriq-loses-bladder-cancer-use-as-fda-crackdown-continues/
